Bethan McLeish1, Anna Morris2, Meena Karpoor3, Tehmoor Babar1, Niro Narendran1, Yit Yang1. 1. Ophthalmology Department, New Cross Hospital, Wolverhampton, WV10 0QP, UK. 2. School of Medicine, Cardiff University, University Hospital of Wales, Cardiff, UK. 3. Ophthalmology Department, New Cross Hospital, Wolverhampton, WV10 0QP, UK. Meena.Karpoor@nhs.net.
Abstract
BACKGROUND: The primary aim was to investigate outcome of the decision making on duration of injection intervals between injection visits over the first 2 years of a treat and extend regimen. METHOD: Consecutive patients receiving Aflibercept for treatment naïve neovascular age-related macular degeneration between 01.01.2016 and 15.07.2017 were identified from our departmental register. Retrospective data collected on all visits over 24 months were classified into three groups: (A) Without Interval Decision Events (IDE)" Injection only" (B) IDE resulting in injection intervals of <5 weeks and (C) IDE resulting in intervals of >5 weeks. The primary outcome was number of successful IDE relative to the total visits in Group C. Successful decision making was defined as absence of worsening of visual acuity (>5 L) or central retinal thickness (>50 microns) at the subsequent visit. Secondary visual and anatomical outcomes at 24 months were also evaluated. RESULTS: Data from 56 eyes of 50 patients were included in the study. Visual acuity improved by +7.11 L at 24 months. Forty one patients with unilateral therapy made 721 visits: 280 visits (38.8%) were group A; 164 visits (22.8%) were group B and 277 visits (38.4%) were group C. Average interval in Group C was 8.9 weeks (range 5-15). The success rate of extension was 95.31% (264/277 visits). CONCLUSION: These metrics for evaluating the decision making aspect of disease activity monitoring may be useful for monitoring performance and have given us a more realistic view and expectations of what can be achieved using this regime to optimise the timing of injections.
BACKGROUND: The primary aim was to investigate outcome of the decision making on duration of injection intervals between injection visits over the first 2 years of a treat and extend regimen. METHOD: Consecutive patients receiving Aflibercept for treatment naïve neovascular age-related macular degeneration between 01.01.2016 and 15.07.2017 were identified from our departmental register. Retrospective data collected on all visits over 24 months were classified into three groups: (A) Without Interval Decision Events (IDE)" Injection only" (B) IDE resulting in injection intervals of <5 weeks and (C) IDE resulting in intervals of >5 weeks. The primary outcome was number of successful IDE relative to the total visits in Group C. Successful decision making was defined as absence of worsening of visual acuity (>5 L) or central retinal thickness (>50 microns) at the subsequent visit. Secondary visual and anatomical outcomes at 24 months were also evaluated. RESULTS: Data from 56 eyes of 50 patients were included in the study. Visual acuity improved by +7.11 L at 24 months. Forty one patients with unilateral therapy made 721 visits: 280 visits (38.8%) were group A; 164 visits (22.8%) were group B and 277 visits (38.4%) were group C. Average interval in Group C was 8.9 weeks (range 5-15). The success rate of extension was 95.31% (264/277 visits). CONCLUSION: These metrics for evaluating the decision making aspect of disease activity monitoring may be useful for monitoring performance and have given us a more realistic view and expectations of what can be achieved using this regime to optimise the timing of injections.
Authors: Victor M Villegas; Luis A Aranguren; Jaclyn L Kovach; Stephen G Schwartz; Harry W Flynn Journal: Expert Opin Drug Deliv Date: 2016-08-02 Impact factor: 6.648
Authors: Robyn H Guymer; Caroline M Markey; Ian L McAllister; Mark C Gillies; Alex P Hunyor; Jennifer J Arnold Journal: Ophthalmology Date: 2018-11-29 Impact factor: 12.079
Authors: Charles C Wykoff; Daniel E Croft; David M Brown; Rui Wang; John F Payne; Lloyd Clark; Nizar Saleh Abdelfattah; SriniVas R Sadda Journal: Ophthalmology Date: 2015-09-29 Impact factor: 12.079
Authors: Daniel F Martin; Maureen G Maguire; Stuart L Fine; Gui-Shuang Ying; Glenn J Jaffe; Juan E Grunwald; Cynthia Toth; Maryann Redford; Frederick L Ferris Journal: Ophthalmology Date: 2020-04 Impact factor: 12.079
Authors: Rahul N Khurana; Ehsan Rahimy; W Anthony Joseph; Namrata Saroj; Andrea Gibson; Robert Vitti; Alyson J Berliner; Karen Chu; YenChieh Cheng; David S Boyer Journal: Am J Ophthalmol Date: 2019-01-19 Impact factor: 5.258